Devyani Goswami, Amity University Kolkata
Nanette Cocero, global president, vaccines, of Pfizer announced that their tick-borne encephalitis vaccine (TBE) has been approved for a priority review from the US Food and Drug Administration (FDA).
Once approved the vaccine promises to cure tick-borne encephalitis epidemics all across the US. The vaccine has to be subjected twice in a life-time to develop immunity. The clinical trials performed showed 96-99% immunity development across two ages of development 1- 15 years old and 16-65 years old. The vaccine is considered to be more effective on people who were given two doses of it.
Pfizer waits for the approval, which said to declared in August 2021, six months after the application submission date. Once they get the prescription drug user fee act (PDUFA), they would be stated that this would further improve the condition of people suffering from severe conditions.
Also read:New Research Reveals Androgen Receptor promotes Cancer
One thought on “Priority Review for Pfizer’s tick-borne encephalitis vaccine in the US”